BioMarin updates plans for three late-stage programs

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gave R&D updates on three late-stage programs: achondroplasia therapy vosoritide ( BMN 111), phenylketonuria (PKU) treatment pegvaliase ( BMN 165), and cerliponase alfa ( BMN 190) to treat late-infantile neuronal ceroid lipofuscinosis type 2

Read the full 388 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE